Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models

Cancer Biology and Therapy

Volumn 10, Issue 1, 2010, Pages 38-43

  Sun, Haihao ^a   Pisle, Stephen ^a   Gardner, Erin R ^b   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Focal adhesion kinase; In vivo; Luciferase; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; INTEGRIN; LUCIFERASE; LUCIFERIN; PF 562271;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CELL STRAIN; CELL STRAIN PC 3M LUC C6; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE TUMOR; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 77954406994     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.1.11993     Document Type: Article

References (15)

1. Johnson TR, Khandrika L, Kumar B, Venezia S, Koul S, Chandhoke R, et al. "Focal Adhesion Kinase Controls Aggressive Phenotype of Androgen-Independent Prostate Cancer." Mol Cancer Res 2008; 6:1639-48.
2. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al. "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271." Cancer Res 2008; 68:1935-44.
3. Gabarra-Niecko V, Schaller MD, Dunty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003; 22:359-74. (Pubitemid 36791892)
4. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal adhesion kinase in cancer - a new therapeutic opportunity. Na Rev Cancer 2005; 5:505-15.
5. Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. "In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer." Clin Exp Metastasis 2003; 20:745-56.
6. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. "Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype." J Clin Oncol 2005; 23:8232-41.
7. Bagi CM, Roberts WG, Andresen CJ. "Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases." Cancer 2008; 112:2313-21.
8. Contag CH, Jenkins D, Contag PR, Negrin RS. "Use of reporter genes for optical measurements of neoplastic disease in vivo." Neoplasia 2000; 2:41-52. (Pubitemid 30123179)
9. Contag PR, Olomu IN, Stevenson DK, Contag CH. "Bioluminescent indicators in living mammals." Nat Med 4:245-7.
10. Honigman A, Zeira E, Ohana P, Abramovitz R, Tavor E, Galun E, et al. "Imaging transgene expression in live animals." Mol Ther 2001; 4:239-49.
11. Carlsen H, Moskaug JØ, Fromm SH, Blomhoff R. "In vivo imaging of NFkappaB activity." J Immunol 2002; 168:1441-6.
12. Zhang Y, Bressler JP, Neal J, Lal B, Bhang HE, Laterra J, Pomper MG. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res 2007; 67:9389-97.
13. Hollingshead MG, Bonomi CA, Borgel SD, Carter JP, Shoemaker R, Melillo G, Sausville EA. "A potential role for imaging technology in anticancer efficacy evaluations." Eur J Cancer 2004; 40:890-8.
14. Bagi CM, Christensen J, Cohen DP, Roberts WG, Wilkie D, Swanson T, et al. "Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model." Cancer Biol Ther 2009; 8:856-65.
15. Zetter BR. "Angiogenesis and Tumor Metastasis." Ann Rev Med 1998; 49:407-24.